Juno licenses CAR therapy from Opus Bio

Juno Therapeutics Inc. (Seattle, Wash.) licensed from Opus Bio Inc. (Greenwich, Conn.) a candidate that uses chimeric antigen receptor (CAR) technology to target CD22. Financial terms were not disclosed and both companies declined to discuss details of the deal.

Juno is in a quiet period after filing for an IPO in November (see BioCentury Extra, Nov. 17). ...